– Dow Jones Citing WSJ
Revance To Present Data From Phase 2 JUNIPER Clinical Trial Evaluating DAXXIFY At MDS Congress Sept. 16
- Oral poster showcasing positive results from Revance's Phase 2 JUNIPER clinical trial, which demonstrated long-term efficacy and safety with DAXXIFY™ for the treatment of upper limb spasticity (ULS)